Discovery of Phloroglucinol Derivatives as a New Type of Nonnucleoside Inhibitors with Anti-herpes Simplex Virus Type 1 Activity

also showed efficacy in vivo against HSV-1 infection via topical administration. These findings highlight a new type of anti-HSV-1 inhibitors with a mechanism distinct from that of ACV, offering new avenues for anti-HSV-1 drug development.